Fed. Circ. Nixes More Of Inomax Patent After PTAB Review
The Federal Circuit on Wednesday upheld the Patent Trial and Appeal Board's decision to invalidate the bulk of a Mallinckrodt patent on respiratory drug Inomax, then canceled an additional claim that...To view the full article, register now.
Already a subscriber? Click here to view full article